Gastrointestinal Cancer News

Thermo Fisher Scientific and Agios Pharmaceuticals entered into a collaboration agreement to develop and commercialize a next-generation sequencing oncology companion diagnostic for ivosidenib to identify IDH1 mutations in patients with cholangiocarcinoma.

Rare malignancies accounted for about one in five cancer diagnoses in the United States from 2009 to 2013, according to an American Cancer Society report published in CA: A Cancer Journal for Clinicians.

Despite colon cancer being part of our bread and butter routine, I found myself reading this month’s cover story and realizing that anal cancer is a bit of a stepchild within our specialty. Anal cancer is so different from rectal and colon that a lot of us, as gastroenterologists, don’t feel comfortable with it.

Researchers from Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine received a 5-year, $9 million grant from NCI to investigate why mortality rates are higher among black cancer survivors.

The use of capecitabine as adjuvant therapy significantly extended survival of patients with biliary tract cancer, according to results of the BILCAP clinical trial scheduled for presentation at the ASCO Annual Meeting.

Regular consumption of tree nuts conferred considerable benefit to patients with stage III colon cancer, according to observational study results scheduled for presentation at the ASCO Annual Meeting.

Patients with stage III colon cancer had lower risk for death if they had a healthy weight, engaged in physical activity, and ate a well-rounded diet with little alcohol and red meat, according to study results scheduled for presentation at the ASCO Annual Meeting.

An uptake in cancer screening after implementation of the Affordable Care Act in 2014 has shifted the diagnosis of breast, lung and colorectal cancers to an earlier, more treatable stage, according to data scheduled for presentation at the ASCO Annual Meeting.

Nivolumab appeared safe and effective in the treatment of patients with esophageal cancer, according to results of a phase 2 clinical trial.

The FDA granted breakthrough therapy designation to entrectinib for the treatment of NTRK fusion–positive locally advanced or metastatic solid tumors, according to the drug’s manufacturer.